文献速递慢性肾脏病

晚期糖基化终产物在慢性肾脏病发病机制中的作用

Advanced glycation end products in the pathogenesis of chronic kidney disease.
PubMed 文献 · Kidney Int · 2018-02-22

晚期糖基化终产物(AGEs)是葡萄糖及相关代谢物自发反应形成的蛋白质翻译后修饰,包括MG-H1、CML和glucosepane等,参与慢性肾脏病(CKD)发生发展。AGE修饰蛋白经细胞蛋白酶解形成AGE游离加合物,随肾小球滤过率下降在血浆中显著蓄积;MG二羰基应激是CKD特征,由肾脏Glo1下调驱动。RAGE在CKD中重要但体内与AGEs的相互作用尚不明确;Glo1诱导剂(如反式白藜芦醇-橙皮素联合)在临床试验中改善胰岛素抵抗和血管炎症,可能用于糖尿病肾病治疗。

要点

  • AGEs(MG-H1、CML、glucosepane等)参与CKD发生发展。
  • AGE游离加合物随GFR下降在血浆中显著蓄积。
  • Glo1诱导剂可能成为糖尿病肾病治疗方向。

核心结论

  • AGEs及其游离加合物在CKD发病中起重要作用,Glo1诱导剂可能用于糖尿病肾病治疗。

研究设计与样本

  • 综述,总结AGEs在CKD发病机制中的作用及相关治疗研究。

主要发现

  • AGE修饰蛋白经蛋白酶解形成AGE游离加合物,随肾小球滤过率下降在血浆中显著蓄积。
  • MG二羰基应激是CKD特征,由肾脏Glo1下调驱动,增加MG-H1形成通量。
  • RAGE在CKD发展中重要,但其体内与AGEs的相互作用尚不明确。
  • 转基因动物模型过表达Glo1可预防糖尿病肾病,促进Glo1诱导剂开发。
  • 反式白藜芦醇-橙皮素联合治疗在临床试验中显著改善胰岛素抵抗和血管炎症。

临床怎么用

  • 关注Glo1诱导剂作为糖尿病肾病潜在治疗策略。

局限性

  • RAGE与AGEs在体内的相互作用仍不明确,其他配体和三元复合物可能影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advanced glycation end products (AGEs) are stable posttranslational modifications of proteins formed by the spontaneous reaction with glucose and related metabolites. Important AGEs quantitatively are methylglyoxal (MG)-derived hydroimidazolone MG-H1, Nε-carboxymethyl-lysine (CML), and glucosepane. They contribute to the development of chronic kidney disease (CKD). Cellular proteolysis of AGE-modified proteins forms AGE free adducts, glycated amino acids, which are cleared by the kidneys and excreted in urine. Dietary AGEs mainly supplement the endogenous flux of AGE free adduct formation. AGE free adducts accumulate markedly in plasma with decline in glomerular filtration rate. A key precursor of AGEs is the dicarbonyl metabolite MG, which is metabolized by glyoxalase 1 (Glo1) of the cytoplasmic glyoxalase system. Proteins susceptible to MG modification are collectively called the dicarbonyl proteome. Abnormal increase of MG dicarbonyl stress is a characteristic of CKD, driven by down-regulation of renal Glo1, increasing flux of MG-H1 formation. Protein inactivation and dysfunction linked to the dicarbonyl proteome contributes to CKD development. The receptor for AGEs, RAGE, is important in development of CKD, but its interaction with AGEs in vivo remains enigmatic; other ligands and ternary complexation may be influential. Prevention of diabetic kidney disease (DKD) by overexpression of Glo1 in transgenic animal models has stimulated the development of small-molecule inducers of Glo1 expression, Glo1 inducers, to prevent AGE formation. trans-Resveratrol-hesperetin combination therapy is a Glo1 inducer. In clinical trial it demonstrated a profound improvement in insulin resistance and vascular inflammation. It may find future therapeutic application for treatment of DKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Rabbani N, Thornalley PJ. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int. 2018. PMID: 29477239. doi:10.1016/j.kint.2017.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。